These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 26032687)
21. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells. Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772 [TBL] [Abstract][Full Text] [Related]
22. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176 [TBL] [Abstract][Full Text] [Related]
23. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152 [TBL] [Abstract][Full Text] [Related]
24. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945 [TBL] [Abstract][Full Text] [Related]
25. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells. Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248 [TBL] [Abstract][Full Text] [Related]
27. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib. Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915 [TBL] [Abstract][Full Text] [Related]
28. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. Zhao Q; Kretschmer N; Bauer R; Efferth T Int J Cancer; 2015 Sep; 137(6):1446-56. PubMed ID: 25688715 [TBL] [Abstract][Full Text] [Related]
29. Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. Mizuuchi H; Suda K; Sato K; Tomida S; Fujita Y; Kobayashi Y; Maehara Y; Sekido Y; Nishio K; Mitsudomi T PLoS One; 2015; 10(4):e0123901. PubMed ID: 25875914 [TBL] [Abstract][Full Text] [Related]
30. Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. Halatsch ME; Löw S; Mursch K; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI; Feuerhake F J Neurosurg; 2009 Aug; 111(2):211-8. PubMed ID: 19301967 [TBL] [Abstract][Full Text] [Related]
31. Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib. Löw S; Vougioukas VI; Hielscher T; Schmidt U; Unterberg A; Halatsch ME Anticancer Res; 2008; 28(6A):3729-32. PubMed ID: 19189657 [TBL] [Abstract][Full Text] [Related]
32. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. Xie C; Jin J; Bao X; Zhan WH; Han TY; Gan M; Zhang C; Wang J Oncotarget; 2016 Jan; 7(1):610-21. PubMed ID: 26575584 [TBL] [Abstract][Full Text] [Related]
34. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H Cells; 2019 Apr; 8(4):. PubMed ID: 31013819 [TBL] [Abstract][Full Text] [Related]
35. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159 [TBL] [Abstract][Full Text] [Related]
36. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062 [TBL] [Abstract][Full Text] [Related]
37. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964 [TBL] [Abstract][Full Text] [Related]
38. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Sui H; Shi C; Yan Z; Li H Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641 [TBL] [Abstract][Full Text] [Related]
39. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579 [TBL] [Abstract][Full Text] [Related]
40. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]